Evaluation of the frequency of gastrointestinal adverse events associated with the use of prolonged-release metformin hydrochloride
Avaliação da frequência de eventos adversos gastrointestinais associados ao uso de cloridrato de metformina de liberação prolongada
Resumo
Diabetes mellitus is defined by hyperglycemia resulting from impaired insulin action or distress, or both. Metformin is widely prescribed to control the disease and the most common adverse events caused by its use are diarrhea, nausea and/or abdominal discomfort. We evaluated the frequency profile of gastrointestinal adverse events associated with the use of metformin. This is a cross-sectional observational study, in which the occurrence of diarrhea in patients with type 2 diabetes mellitus who started treatment with metformin hydrochloride at a dose of 500 mg of prolonged release was reported. 12 (41.37%) participants were male and 17 (58.62%) were female. Diarrhea was present (n=16) in more than half of the patients (55.2%) who used the drug. Patients had an average of 12 episodes of diarrhea per month. There was also the presence of abdominal discomfort (n=7), in which 24.1% reported being very high. The study showed that the extended-release drug metformin hydrochloride 500 mg can cause gastrointestinal adverse events at the start of treatment and lasts for approximately twelve days.
Downloads
Referências
AGGARWAL, N. et al. Metformin extended‐release versus immediate‐release: an international, randomized, double‐blind, head‐to‐head trial in pharmacotherapy‐naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism, v. 20, n. 2, p. 463–467, 2018. https://doi.org/10.1111/dom.13104.
BARROS, L. S. A. Alterações de parâmetros bioenergéticos hipocampais induzidos por hiperglicemia crônica e derivados da glicose em células neurais. Universidade Federal de Santa Catarina. 2019.
BONNET, F.; SCHEEN, A. Understanding and overcoming metformin gastrointestinal intolerance. Journal Diabetes, Obesity and Metabolism, Bélgica, v. 19, n. 4, p. 473-481. 2017. https://doi.org/10.1111/dom.12854.
DEROSA, G. et al. Efeitos da liberação prolongada de metformina em comparação com a fórmula de liberação imediata no controle glicêmico e variabilidade glicêmica em pacientes com diabetes tipo 2. National Center for Biotechnology Information, v. 16, n. 11, p. 1481-1488, 2017.
FATIMA, M.; SADEEQA, S.; NAZIR, S. U. R. Metformin and its gastrointestinal problems: a review. Biomedical Research, v. 29, n. 11, 2018. https://doi.org/10.4066/biomedicalresearch.40-18-526.
GOLBERT, A. et al. Diretrizes da Sociedade Brasileira de Diabetes 2019-2020. Soc. Brasileira de Diabetes (BR), 2019.
IDF. International Diabetes Federation. IDF Atlas. 10. ed. Bruxelas: International Diabetes Federation; 2021.
JUNIOR, A. E. M. et al. Quality assessment of metformin hydrochloride tablets commercially available in Brazil. Journal of Applied Pharmaceutical Sciences, n.7, p. 117-127, 2020.
KOEPSELL, H; ENDOU, H. The SLC22 drug transporter family. Pflugers Arch, v. 447, n. 5, p. 666-676, 2004. https://doi.org/10.1007/s00424-003-1089-9.
KUMAR, K. M. P. et al. Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulation in Indian patients with type 2 diabetes 18 mellitus: a postmarketing observational study. International Journal of General Medicine, v. 12, p. 147-159, 2019. https://doi.org/10.2147%2FIJGM.S179622.
KUMAR, V.; GUPTA, A. Comparative in-vitro evaluation of four different brands of metformin HCl available in Kanpur district, India. Der Pharmacia Lettre. 2016. Disponível em: https://www.scholarsresearchlibrary.com/articles/comparativeinvitro-evaluation-of-four-different-brands-of-metformin-hclavailable-in-kanpur-districtindia.pdf. Acesso em: 1 dez. 2020.
LUI, M. et al. Development and validation of a patientreported questionnaire assessing systemic therapy induced diarrhea in oncology patients. Health and Quality of Life Outcomes, v. 15, n. 1, p. 1-12, 2017. https://doi.org/10.1186/s12955-017-0794-6.
MALTA, M. et al. Iniciativa STROBE: subsídios para a comunicação de estudos observacionais. Rev. Saúde Pública, v. 44, n. 3, p. 559-65, 2010.
MCCREIGHT, L. J.; BAILEY, C. J.; PEARSON, E. R. Metformin and the gastrointestinal tract. National Center for Biotechnology Information, v. 59, n. 3, p. 426-435, 2016. https://doi.org/10.1007/s00125-015-3844-9.
PEREIRA, A. C. C. et al. Relação entro o uso de metformina e a deficiência de vitamina B12 em pacientes com diabetes mellitus tipo 2. Rev. Eletrônica Acervo Saúde, v. 12, n. 10, p. e4469-e4469, 2020.
RANGEL, E. S.; INZUCCHI, S. E. METFORMINA: uso clínico em diabetes tipo 2. p. 1586-1593. 2017.
SILVA, P. Farmacologia. 7. ed. Rio de Janeiro: Guanabara Koogan, 2006.
SIQUEIRA, L. O.; FRIGERI, F. C. Uso da metformina como agente emagrecedor. Revista Brasileira De Obesidade, Nutrição e Emagrecimento, v. 12, n. 71, p. 285-292, 2018.
TAN, J. et al. Long-acting metformin vs. Metformin immediate release in patients with type 2 diabetes: a systematic review. Frontiers in pharmacology, v. 12, p. 669814, 2021. https://doi.org/10.3389/fphar.2021.669814.